An interventional study of 10% 35-kDa hyaluronan fragment HA35 topical gel in Dry Eye Symptoms, Ocular Fatigue and Periorbital Wrinkles, sponsored by Nakhia Impex LLC. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Nakhia Impex LLC · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Asthenopia with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Asthenopia · China.
Among the 14 studies in Asthenopia with a site in China, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 13 with no phase, and was the 14th registered.
68 studies on the registry are indexed under Asthenopia; 11 are open to participants now.
Browse Asthenopia studies →2 of the 14 studies in Asthenopia with a site in China are open now. Recruiting first, the newest first:
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 18–35 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 4 Asthenopia studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 30 is below the median of 55 across 57 interventional studies indexed under Asthenopia.
Median enrollment 46 across the 14 interventional studies. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 5 most frequent:
Nakhia Impex LLC is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Nakhia Impex LLC has 1 study filed under Asthenopia — fewer than ten, so there is no comparison to draw.
2 of the studies in Asthenopia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07942233Nakhia Impex LLC10% 35-kDa Hyaluronan Fragment (HA35) Gel for Periocular Comfort and Aesthetics | 2027-01-07 |
| NCT07706231Zhongshan Ophthalmic Center, Sun Yat-sen UniversityA Study of Full-Spectrum Screen Lighting for Reducing Screen-Related Eye Fatigue and Dry Eye | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Asthenopia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To explore the efficacy and safety of 10% 35-kDa hyaluronan fragment (HA35) gel with occlusive dressing applied externally to periocular skin for improvement of ocular comfort symptoms and periocular aesthetic appearance. Participants apply gel once-daily with occlusive covering for ≥2 hours or overnight for 7 consecutive days. Assess subjective ocular discomfort, eye fatigue, conjunctival appearance, periocular wrinkle, eyelid thickness and local safety. **No gel is instilled into the eye globe.
This is a prospective, single-arm, open-label pilot clinical study. Eligible participants receive 10% 35-kDa sodium hyaluronate fragment (HA35) gel, applied as a generous even layer onto external periocular skin with eyes closed. A 10×10 cm non-woven wound dressing or steam eye-mask is placed over treatment area for occlusion to prevent drying. Each application remains in-place for ≥2 hours or overnight, once daily for 7 consecutive days. The product is for **external periocular skin use only; must NOT be instilled inside the eye**. Subjective ocular symptoms and investigator-rated periocular aesthetic signs will be evaluated at baseline, 20 minutes after first application, day-7 end-of-treatment visit. Adverse events and local tolerability are monitored throughout study. Target enrollment is 30 adult participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: 10% 35-kDa hyaluronan fragment HA35 topical gel
10% 35-kDa sodium hyaluronate gel, external periocular skin only (eyes closed, no intra-ocular instillation). Apply generous even layer; cover with occlusive dressing/steam eye-mask; leave ≥2 hours or overnight, once daily for 7 consecutive days.
Ocular Discomfort / Pain / Itch NRS Score
0-10 numerical rating scale participant-reported score for ocular discomfort, pain or itch; 0=no discomfort, 10=maximum discomfort
Time frame: Baseline, 20 minutes after first application, Day-7 post-7-applications
Ocular Fatigue NRS Score
Participant-reported 0-10 NRS for subjective eye fatigue; 0=no fatigue, 10=severe fatigue
Time frame: Baseline, 20 minutes after first application, Day-7 post-7-applications
Subjective Reduced Visual Brightness NRS Score
Participant-reported 0-10 NRS for perceived reduction of visual brightness; 0=no reduction,10=maximum reduction
Time frame: Baseline, Day-7
Ocular / Palpebral Conjunctival Appearance Composite Score
Investigator-rated composite 0-10 score for conjunctival redness, swelling, congestion; 0=normal appearance; 10=severe redness/swelling/congestion.
Time frame: Baseline, Day-7
Lateral Canthal Wrinkle Severity NRS Score
Investigator visual rating 0-10 for lateral canthal wrinkle severity; 0=no wrinkle; 10=maximum wrinkle severity
Time frame: Baseline, Day-7
Upper-Eyelid Thickness / Puffiness NRS Score
Investigator visual-tactile rating 0-10 for upper-eyelid thickness and puffiness; 0=no puffiness/thickening;10=severe puffiness
Time frame: Baseline, Day-7
Palpebral Fissure Enlargement Change Score
Investigator-rated change-from-baseline score; 0=no change; higher value indicates greater improvement of palpebral fissure opening appearance
Time frame: Baseline, Day-7
Periocular Tissue-Softening Change Score
Investigator visual-palpation change-from-baseline score;0=no change; higher value indicates greater softening/relaxation of periocular tissue
Time frame: Baseline, Day-7
Participant Overall Satisfaction Questionnaire Score
Participant 0-10 satisfaction score for overall periocular and ocular-comfort improvement;0=most dissatisfied, 10=most satisfied
Time frame: Day-7 end-of-treatment visit
Adverse Event Incidence
Incidence of product-related local or ocular adverse reactions, including stinging, redness, irritation, itching, eye irritation
Time frame: Throughout 7-day study period
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jan 2027, 1 month later.
Of 38 interventional studies with no phase under Asthenopia, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 1 month is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.